Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vanguard Total Stock Market ETF (NY:VTI)

336.33 -3.94 (-1.16%)
Streaming Delayed Price Updated: 1:56 PM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vanguard Total Stock Market ETF

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder ↗
The company applied for approval of the gene therapy in the treatment of Glycogen Storage Disease Type Ia or Von Gierke disease. 
Via Stocktwits
News headline image
FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy ↗
Fortress said that its majority-owned unit Cyprium Therapeutics has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher to Sentynl... 
Via Stocktwits
News headline image
Is Microsoft Down? Downdetector Reports Issues With Azure, Outlook, MSFT 365 ↗
Microsoft flagged that services that require Multi-Factor Authentication may return gateway timeout errors for users in the U.S. 
Via Stocktwits
News headline image
Eli Lilly Announces New Version Of Zepbound With A Month’s Worth Of Doses In KwikPen — How Much Will It Cost? ↗
The new Zepbound KwikPen can be purchased by cash-paying customers through LillyDirect, Eli Lilly’s direct-to-customer website. 
Via Stocktwits
News headline image
ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 1% Pre-Market ↗
Net product revenue in the fourth quarter surged 431% to $38.3 million, above estimates of $37.8 million, according to Fiscal.ai data 
Via Stocktwits
News headline image
Palo Alto Networks Removed From Wedbush’s ‘Best Ideas List’ — Here’s Why ↗
According to TheFly, Wedbush’s Dan Ives cited investment price discipline as the reason for the removal of PANW from the list. 
Via Stocktwits
Topics Artificial Intelligence Government
News headline image
Nvidia Must Deliver A Blowout To Reassure Investors That AI Trade Is Still Young, Expert Says Ahead Of NVDA's Q4 Results ↗
Being at the epicenter of AI, Ken Mahoney hopes that Nvidia will offer clues as to what’s happening in the technology sector. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
How Broad Market ETFs Like VTI Can Support Long-Term Portfolio Stability ↗
Diversification is overlooked by many investors, but it can be a powerful tool for building long-term wealth. 
Via The Motley Fool
Topics ETFs Economy
News headline image
DPZ Stock Pops Pre-Market As Domino’s ‘Hungry For More’ Strategy Drives 32nd Straight Year Of International Same-Store Sales Growth ↗
The company said that its market share in the U.S. increased by another point, keeping it ahead of the Quick Service Restaurant pizza category. 
Via Stocktwits
Topics Government
News headline image
Why Did ACLX Stock Surge 80% In Pre-Market Today? ↗
Gilead Sciences announced an agreement to acquire Arcellx in a $7.8 billion deal. 
Via Stocktwits
News headline image
You Don't Need to Buy Apple Stock. Here's Why ↗
The tech giant has been a big winner for years, but there's a simple reason why many investors can leave it out of their portfolios 
Via The Motley Fool
News headline image
2 ETFs Robinhood Retail Investors Favor Over Palantir, Alphabet, Meta, and Netflix Shares ↗
It is no wonder, considering this was the best January ever for ETF inflows. 
Via The Motley Fool
Topics ETFs
News headline image
SVRA Stock Rises After Hours As FDA Grants Priority Review For Lung Disorder Therapy ↗
The company is seeking approval for Molbreevi to treat patients with Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP). 
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
VNDA Stock Rallies After-Hours As FDA Approves Schizophrenia, Bipolar Disorder Drug ↗
This is the second Vanda drug to be approved in the span of a few months, after the approval of Nereus in December. 
Via Stocktwits
News headline image
ImmunityBio Inks Partnerships To Launch Cancer Drug In Saudi Arabia Amid Expansion Efforts ↗
ImmunityBio announced that it has partnered with Biopharma and Cigalah and hopes to launch Anktiva across the broader Middle East and North Africa (MENA) region over time. 
Via Stocktwits
News headline image
Lucid Reportedly Lays Off 12% Workforce Amid Gravity SUV Ramp-Up ↗
Techcrunch reported on Friday, citing an internal memo, that the layoffs are likely to impact hundreds of employees. 
Via Stocktwits
Topics Workforce
News headline image
GE Stock On Track To Hit All-Time High: Morgan Stanley Calls It A ‘Structural Winner’, Flags 27% Upside ↗
Morgan Stanley initiated coverage of the stock with an ‘Overweight’ rating and a price target of $425, according to The Fly. 
Via Stocktwits
News headline image
GRAL Stock Slumps After Hours As Trial For Cancer Test Fails To Show Reduction In Late-Stage Diagnoses ↗
The trial did not show a statistically significant reduction in Stage III-IV cancer diagnoses, the company said. 
Via Stocktwits
Topics Artificial Intelligence Death
News headline image
ARDX Stock Slips After Hours As Q4 Earnings Disappoint: Retail Sees Ibsrela Driving Outperformance In Time ↗
The company reported no earnings for the fourth quarter, compared to an analyst estimate of $0.01 per share. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Tesla CEO Elon Musk Envisions Coffee Shops At Superchargers Manned By Optimus Bots ↗
Musk said that the company might consider the idea in response to an X user. 
Via Stocktwits
Topics Earnings
News headline image
Trevian Wealth Management Buys $2.7 Million of Fidelity Nasdaq Composite Index ETF ↗
Fidelity Nasdaq Composite Index ETF tracks thousands of U.S.-listed growth and technology stocks for broad market exposure. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
JNJ Stock Rises As Drugmaker Reportedly Eyes Orthopedics Segment Sale For Up To $20B ↗
Bloomberg reported, citing people familiar with the matter, that DePuy Synthes could be valued at more than $20 billion in a sale. 
Via Stocktwits
News headline image
CORT Stock Drops After Appeals Court Sides With Teva In Korlym Patent Fight ↗
The ruling pertains to Corcept’s Korlym tablets for the treatment of Cushing syndrome. 
Via Stocktwits
Topics Intellectual Property
News headline image
BKNG Stock Falls To Over 16-Month Lows – Brokerages Flag AI-Related Uncertainties ↗
Multiple brokerages, including Barclays and Oppenheimer, slashed their price targets despite a better-than-expected fourth quarter print. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Cassava Sciences Says DOJ Has Closed Probe Into Allegations Around Its Alzheimer’s Program ↗
The probes into the company by both the DOJ and the SEC have now been closed. 
Via Stocktwits
Topics Regulatory Compliance
News headline image
This Heavily Sold Nano-Cap Skincare Stock Jumped 12% Pre-Market – What Happened? ↗
PMGC's unit, NorthStrive Biosciences, filed 10 new U.S. patent applications for EL-22 and EL-32 technologies in the animal health and agriculture markets. 
Via Stocktwits
Topics Emissions Intellectual Property
News headline image
CVNA Stock Slumps 10% Pre-Market: Wall Street Questions 2026 Visibility, Retail Flags ‘Deterioration’ ↗
Multiple brokerages slashed Carvana’s price target after the company’s fourth-quarter earnings fell below Street estimates. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Amazon Pips Walmart To Become World’s Biggest Company By Revenue ↗
Amazon reported revenue of $716.9 billion in the fiscal year 2025, while its retail rival Walmart posted $713.2 billion in revenue during the year. 
Via Stocktwits
News headline image
LMND Stock Soars Pre-Market: Lemonade Extends Premium Growth Streak To Ninth Consecutive Quarter ↗
Lemonade reported a 31% year-on-year growth in In Force Premium to $1.24 billion in the fourth quarter. 
Via Stocktwits
Topics Government
News headline image
Hims & Hers Health Makes Australia, Japan Foray With $1.15 Billion Eucalyptus Acquisition ↗
Hims & Hers Health, Inc. (HIMS) announced on Thursday that it has signed a definitive agreement to acquire Eucalyptus in a deal valued at up to $1.15 billion. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.